1. Characteristics and outcomes of 118,155 COVID-19 individuals with a history of cancer in the United States and Spain
- Author
-
Diana Puente Dr, Daniel R Morales Dr, Anthony G Sena Mr, Heba Alghoul Mr, Elena Roel Mrs, Donna Rivera Mrs, Nigam Shah Dr, Matthew Spotnitz Mr, Vignesh Subbian Dr, Jose D Posada Dr, Clair Blacketer Mrs, Andrea Pistillo Mr, Albert Prats-Uribe Mr, Lana Yh Lai Dr, Eng Hooi Tan Dr, Marc A Suchard Dr, Anna Ostropolets Mrs, Thamir M Alshammari Dr, Kristine E Lynch Dr, George Hripcsak Mr, Mengchun Gong Mr, Laura Hester Dr, Frank DeFalco Mr, Asieh Golozar Dr, Thomas Falconer Mr, Maria Aragon Mrs, Christian G Reich Dr, Hokyun Jeon Mr, Karishma Shah Mrs, Scott L Duvall Dr, Talita Duarte-Salles Dr, Lisa M Schilling Mrs, Lin Zhang Dr, Karthik Natarajan Dr, Martina Recalde Mrs, Michael E Matheny Mr, Carlos Areia Mr, Fredrik Nyberg Dr, Daniel Prieto-Alhambra Dr, Annalisa Trama Dr, Patrick Ryan Dr, Kristin Kostka Mrs, William Carter Mr, Waheed-Ul-Rahman Ahmed Mr, Isabelle Soerjomataram Dr, Aedin C Culhane Dr, Yang Shen Mr, Osaid Alser Mr, Dalia Dawoud Dr, Ying Zhang Dr, Sergio Fernandez-Bertolin Mr, Jitendra Jonnagaddala Dr, and Paula Casajust Mrs
- Subjects
Mortaility ,medicine.medical_specialty ,COVID19 ,SARS-CoV-2 ,Characterisation ,business.industry ,Cancer ,Hospital admission ,medicine.disease ,Breast cancer ,Internal medicine ,Health care ,Cohort ,medicine ,Etiology ,Observational study ,business ,Adverse effect ,Cohort study - Abstract
PurposeWe aimed to describe the demographics, cancer subtypes, comorbidities and outcomes of patients with a history of cancer with COVID-19 from March to June 2020. Secondly, we compared patients hospitalized with COVID-19 to patients diagnosed with COVID-19 and patients hospitalized with influenza.MethodsWe conducted a cohort study using eight routinely-collected healthcare databases from Spain and the US, standardized to the Observational Medical Outcome Partnership common data model. Three cohorts of patients with a history of cancer were included: i) diagnosed with COVID-19, ii) hospitalized with COVID-19, and iii) hospitalized with influenza in 2017-2018. Patients were followed from index date to 30 days or death. We reported demographics, cancer subtypes, comorbidities, and 30-day outcomes.ResultsWe included 118,155 patients with a cancer history in the COVID-19 diagnosed and 41,939 in the COVID-19 hospitalized cohorts. The most frequent cancer subtypes were prostate and breast cancer (range: 5-19% and 1-14% in the diagnosed cohort, respectively). Hematological malignancies were also frequent, with non-Hodgkin’s lymphoma being among the 5 most common cancer subtypes in the diagnosed cohort. Overall, patients were more frequently aged above 65 years and had multiple comorbidities. Occurrence of death ranged from 8% to 14% and from 18% to 26% in the diagnosed and hospitalized COVID-19 cohorts, respectively. Patients hospitalized with influenza (n=242,960) had a similar distribution of cancer subtypes, sex, age and comorbidities but lower occurrence of adverse events.ConclusionPatients with a history of cancer and COVID-19 have advanced age, multiple comorbidities, and a high occurence of COVID-19-related events. Additionaly, hematological malignancies were frequent in these patients.This observational study provides epidemiologic characteristics that can inform clinical care and future etiological studies.
- Full Text
- View/download PDF